Molecular Markers in Native American Women With Breast Cancer
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 120
- 主要终点
- Evaluation of a selected panel of molecular markers in tissue specimens from Native American women with breast cancer
研究概览
简要总结
RATIONALE: Studying samples of tumor tissue in the laboratory from Native American women with breast cancer may help doctors identify and learn more about biomarkers related to breast cancer in these patients. It may also help doctors learn more about the prognosis of these patients.
PURPOSE: This laboratory study is looking at biomarkers in Native American women with breast cancer.
详细描述
OBJECTIVES:
- Evaluate a selected panel of molecular markers in tissue specimens from Native American women with breast cancer.
- Determine which molecular markers provide independent prognostic information with respect to traditional prognostic factors in these patients.
- Compare and contrast the prevalence of positivity in Native American women with breast cancer with an age- and stage-matched cohort of Caucasian women with breast cancer enrolled on clinical trial NCCTG-77-30-51 or the Mayo Breast Cancer Registry.
OUTLINE: Immunohistochemistry is performed on tumor samples to analyze the following molecular markers: estrogen receptor, progesterone receptor, c-erbB2, p53, Ki-67, Bcl-2, Bax, cyclin D-1, and insulin-like growth factor-1R.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Evaluation of a selected panel of molecular markers in tissue specimens from Native American women with breast cancer
时间窗: Up to 5 years
Determination of which molecular markers provide independent prognostic information with respect to traditional prognostic factors
时间窗: Up to 5 years
Comparison of the prevalence of positivity in Native American women with breast cancer with an age- and stage-matched cohort of Caucasian women with breast cancer enrolled on clinical trial NCCTG-77-30-51 or the Mayo Breast Cancer Registry
时间窗: Up to 5 years
次要结局
未报告次要终点